Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.

Biotech Giants' Cost Trends: BioMarin vs. Halozyme

__timestampBioMarin Pharmaceutical Inc.Halozyme Therapeutics, Inc.
Wednesday, January 1, 201412976400022732000
Thursday, January 1, 201515200800029245000
Friday, January 1, 201620962000033206000
Sunday, January 1, 201724178600031152000
Monday, January 1, 201831526400010136000
Tuesday, January 1, 201935946600045546000
Wednesday, January 1, 202052427200043367000
Friday, January 1, 202147051500081413000
Saturday, January 1, 2022483669000139304000
Sunday, January 1, 2023577065000192361000
Monday, January 1, 2024580235000159417000
Loading chart...

Data in motion

Cost of Revenue Trends: BioMarin vs. Halozyme

In the competitive landscape of biotechnology, understanding cost dynamics is crucial. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc. have shown distinct trends in their cost of revenue. BioMarin's costs have surged by approximately 345%, peaking in 2023, reflecting their aggressive expansion and increased production capabilities. In contrast, Halozyme's costs have grown by about 747% over the same period, indicating a significant scaling of operations. Notably, BioMarin's cost of revenue consistently outpaced Halozyme's, highlighting their larger operational scale. However, Halozyme's rapid growth in recent years suggests a strategic pivot towards increased market presence. This data provides a window into the strategic financial maneuvers of these biotech giants, offering investors and analysts a deeper understanding of their operational efficiencies and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025